

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

2026 THIRD QUARTERLY REPORT

This announcement is made by 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries collectively, the “**Group**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (the “**SFO**”) (Chapter 571, Laws of Hong Kong) (as defined in the Listing Rules).

The Company and all members of the board of directors (the “**Board**”) warrant that the contents of the information disclosure are true, accurate and complete without containing any false representations, misleading statements or material omissions.

IMPORTANT NOTICE:

1. The Board, the directors and senior management of the Company warrant the truthfulness, accuracy and completeness of the 2026 Third Quarterly Report (the “**Quarterly Report**”), which does not contain any false representations, misleading statements or material omissions, and accept joint and several legal liabilities for its contents.
2. The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) declare that they warrant the truthfulness, accuracy and completeness of the financial information contained in the Quarterly Report.
3. The Quarterly Report was prepared in both Chinese and English. In the event of any discrepancy between the Chinese and English versions, the Chinese version shall prevail. The financial statements and corresponding information contained in the Quarterly Report have been prepared in accordance with the China Accounting Standards for Business Enterprises. Unless otherwise stated, the currency denominations herein are RMB.
4. Whether the financial report of the third quarter has been audited

☐ Yes ☒ No

I. PRINCIPAL FINANCIAL DATA

(I) Principal Accounting Data and Financial Indicators

Whether the Company has made retrospective adjustments or restatements of accounting data of prior years

☐ Yes ☒ No

	The Reporting Period (July– September 2026)	Period-to-period change	From the beginning of the year to the end of the Reporting Period (January– September 2026)	Period-to-period change
Operating income (RMB)	2,319,638,386.27	-18.44%	7,319,308,094.92	-19.71%
Net profit attributable to shareholders of the Company (RMB)	355,906,126.82	-24.76%	1,288,105,339.88	-26.57%
Net profit attributable to shareholders of the Company after deducting extraordinary gains or losses (RMB)	370,178,127.21	-18.39%	1,260,378,995.53	-26.38%
Net cash flow from operating activities (RMB)	–	–	2,491,927,678.82	-1.33%
Basic earnings per share (RMB/share)	0.40	-23.08%	1.45	-26.02%
Diluted earnings per share (RMB/share)	0.40	-23.08%	1.45	-26.02%
Weighted average return on net assets	2.61%	Decreased by 0.8 percentage point	9.22%	Decreased by 3.27 percentage points

	End of the Reporting Period	End of last year	Change
Total assets (RMB)	23,246,190,657.08	23,985,471,448.48	-3.08%
Owners' equity attributable to shareholders of the Company (RMB)	13,019,162,873.15	13,888,350,565.14	-6.26%

(II) Items and Amounts of Extraordinary Gains or Losses

☒ Applicable ☐ Not Applicable

Unit: RMB

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Description
Profit or loss on disposal of non-current assets (including writing-off of accrued impairment provision of assets)	-171,609.56	3,470,310.97	–
Government grants included in the profit or loss for the Period (except for government grants which are closely related to the ordinary corporate business of the Company, conformed to the requirements of national policies, were granted in accordance with determined standards, and had a continuous impact on the Company's profit or loss)	12,819,030.70	52,973,864.34	–
Gains or losses on fair value changes in financial assets and financial liabilities held by non-financial enterprises and gains or losses on disposal of financial assets and financial liabilities, except for effective hedging activities related to the ordinary operating business of the Company	-20,585,288.00	-2,061,052.37	–
Other non-operating income and expenses excluding the above items	-2,687,277.53	-6,638,097.65	–
Less: Effect of income tax	1,737,402.05	7,913,930.77	–
Effect on minority interests (after tax)	1,909,453.95	12,104,750.17	–
Total	-14,272,000.39	27,726,344.35	–

Details of other gain or loss items that fall within the definition of extraordinary gains or losses

☐ Applicable ☒ Not Applicable

The Company has no other gain or loss items that fall within the definition of extraordinary gains or losses.

Explanation on defining the items of extraordinary gains or losses as set out in the “Interpretative Announcement for Information Disclosure of Companies that Issue Securities to the Public No. 1 – Extraordinary Gains or Losses” as items of recurring gains or losses

☐ Applicable ☒ Not Applicable

The Company has not defined any items of extraordinary gains or losses as set out in the “Interpretative Announcement for Information Disclosure of Companies that Issue Securities to the Public No. 1 – Extraordinary Gains or Losses” as items of recurring gains or losses.

(III) Information and Reasons of Changes in Principal Accounting Data and Financial Indicators

☐ Applicable ☒ Not Applicable

II. INFORMATION OF SHAREHOLDERS

(I) Total Number of Ordinary Shareholders and the Number of Preferred Shareholders with Voting Rights Resumed and Information on Shareholdings of the Top 10 Shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	62,628 holders (including 62,609 holders of A shares and 19 holders of H shares ^{Note 1})	Total number of preferred shareholders with voting rights resumed as at the end of the Reporting Period (if any)	–
---	--	--	---

Shareholdings of the Top 10 Shareholders (excluding shares lent through securities lending and refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage (%)	Number of shares held	Number of restricted shares held	Status of pledged, charged or locked up shares	Number
HKSCC Nominees Limited ^(Note 2)	Foreign legal person	33.74%	299,555,200	–	–	–
Joicare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司)	Domestic non-state owned legal person	24.93%	221,376,789	–	–	–
Guangzhou Begol Pharmaceutical and Health Products Import & Export Co., Ltd. (廣州保科力醫藥保健品進出口有限公司)	State-owned legal person	1.95%	17,306,329	17,306,329	Pledged and locked up	17,306,329
Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱製藥有限公司)	Domestic non-state owned legal person	1.90%	16,830,835	–	–	–
Hong Kong Securities Clearing Company Limited	Foreign legal person	1.32%	11,730,718			
Bank of Shanghai Co., Ltd. – Yinhua CSI Innovative Pharmaceutical Industry Exchange-Traded Open-End Index Securities Investment Fund (Yinhua CSI Innovative Pharmaceutical Industry ETF) (上海銀行股份有限公司－銀華中證創新藥產業交易型開放式指數證券投資基金)	Others	0.61%	5,380,071	–	–	–
Bank of China Limited – GF CSI Innovative Pharmaceutical Industry Exchange-Traded Open-End Index Securities Investment Fund (Bank of China Limited – GF CSI Innovative Pharmaceutical Industry ETF) (中國銀行股份有限公司－廣發中證創新藥產業交易型開放式指數證券投資基金)	Others	0.41%	3,669,832	–	–	–
Bank of China Limited – Bosera CSI Dividend Low Volatility 100 Exchange-Traded Open-End Index Securities Investment Fund (中國銀行股份有限公司－博時中證紅利低波動100交易型開放式指數證券投資基金)	Others	0.29%	2,595,600	–	–	–
Guosen Securities Co., Ltd. (國信證券股份有限公司)	State-owned legal person	0.26%	2,281,564	–	–	–
Zhongtai Securities Co., Ltd. – ChinaAMC CNI Free Cash Flow Exchange-Traded Open-End Index Securities Investment Fund (中泰證券股份有限公司－華夏國證自由現金流交易型開放式指數證券投資基金)	Others	0.24%	2,154,539	–	–	–

Shareholdings of the Top 10 Shareholders Not Subject to Selling Restrictions
(excluding shares lent through securities lending and refinancing and shares locked up by senior management)

Name of shareholder	Number of non-restricted shares held	Class of shares	Class of shares	Number
HKSCC Nominees Limited ^(Note 2)	299,555,200	Overseas listed foreign shares		299,555,200
Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司)	221,376,789	Ordinary shares denominated in Renminbi		221,376,789
Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱製藥有限公司)	16,830,835	Ordinary shares denominated in Renminbi		16,830,835
Hong Kong Securities Clearing Company Limited	11,730,718	Ordinary shares denominated in Renminbi		11,730,718
Bank of Shanghai Co., Ltd. – Yinhua CSI Innovative Pharmaceutical Industry Exchange-Traded Open-End Index Securities Investment Fund (Yinhua CSI Innovative Pharmaceutical Industry ETF) (上海銀行股份有限公司－銀華中證創新藥產業 交易型開放式指數證券投資基金)	5,380,071	Ordinary shares denominated in Renminbi		5,380,071
Bank of China Limited – GF CSI Innovative Pharmaceutical Industry Exchange-Traded Open-End Index Securities Investment Fund (Bank of China Limited – GF CSI Innovative Pharmaceutical Industry ETF) (中國銀行股份有限公司－廣發中證創新藥產業 交易型開放式指數證券投資基金)	3,669,832	Ordinary shares denominated in Renminbi		3,669,832
Bank of China Limited – Bosera CSI Dividend Low Volatility 100 Exchange-Traded Open-End Index Securities Investment Fund (中國銀行股份有限公司 －博時中證紅利低波動100交易型開放式指數 證券投資基金)	2,595,600	Ordinary shares denominated in Renminbi		2,595,600
Guosen Securities Co., Ltd. (國信證券股份有限公司)	2,281,564	Ordinary shares denominated in Renminbi		2,281,564
Zhongtai Securities Co., Ltd. – ChinaAMC CNI Free Cash Flow Exchange-Traded Open-End Index Securities Investment Fund (中泰證券股份有限公司－華夏國 證自由現金流交易型開放式指數證券投資基金)	2,154,539	Ordinary shares denominated in Renminbi		2,154,539
Guotai Haitong Securities Co., Ltd. – Tianhong CSI Dividend Low Volatility 100 Exchange-Traded Open-End Index Securities Investment Fund (國泰海通證券股份有限公司－天弘中證紅利 低波動100交易型開放式指數證券投資基金)	2,138,900	Ordinary shares denominated in Renminbi		2,138,900

Description on the connected relationship or acting-in-concert relationship among the aforementioned shareholders	(1) On 2 January 2004, Joicare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司) (“ Joicare ”) and Guangzhou Begol Pharmaceutical and Health Products Import & Export Co., Ltd. (廣州保科力醫藥保健品進出口有限公司) (formerly known as Guangzhou Begol Trading Holdings Limited (廣州市保科力貿易公司)) (“ Begol ”) entered into a Share Transfer and Custody Agreement and a Share Pledge Agreement, pursuant to which the 6,059,428 original domestic legal person shares of the Company held by Begol (the number of shares was increased to 7,877,256 shares after the Company’s implementation of 2014 equity distribution, to 10,240,432 shares after the Company’s implementation of 2016 equity distribution, to 13,312,561 shares after the Company’s implementation of 2017 equity distribution, and to 17,306,329 shares after the Company’s implementation of 2018 equity distribution) were directly transferred, entrusted and pledged to Joicare; (2) Shenzhen Haibin Pharmaceutical Co., Ltd. is a subsidiary controlled by Joicare, in which Joicare directly and indirectly holds 100% equity interest; (3) the Company is not aware of any connected relationship among the other abovementioned shareholders or whether they are persons acting in concert under the provisions of the Administration Measures for the Takeover of Listed Companies.
---	--

Description of the top 10 shareholders involved in margin financing and securities lending business (if any)	None
--	------

- Notes:* 1. The information on the shareholdings of the abovementioned top 10 shareholders is based on the information recorded in the register of members as at 30 September 2026 provided by the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited and Tricor Investor Services Limited in Hong Kong.
2. HKSCC Nominees Limited is the nominee holder of H shares of the Company, and the Company cannot ascertain whether such shares held by it are subject to any pledge or lock-up. The shares held by HKSCC Nominees Limited as nominee include 163,364,672 H shares of the Company held on behalf of Topsino Industries Limited, which is a wholly-owned subsidiary of Joicare, the Company’s controlling shareholder.

Lending of shares by shareholders holding more than 5% of the shares, top 10 shareholders and top 10 shareholders with unrestricted tradable shares in refinancing business

☐ Applicable ☒ Not Applicable

The top 10 shareholders and the top 10 shareholders with unrestricted tradable shares changed from the previous period due to the lending/repayment of refinancing

☐ Applicable ☒ Not Applicable

(II) Total Number of Preferred Shareholders of the Company and Shareholdings of the Top 10 Preferred Shareholders

☐ Applicable ☒ Not Applicable

III. OTHER IMPORTANT EVENTS

☐ Applicable ☒ Not Applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statements

Consolidated Balance Sheet

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount at the end of the Period	Amount at the beginning of the year
Current assets:		
Monetary fund	7,250,407,895.67	9,305,381,624.06
Financial assets held for trading	67,221,279.52	1,344,668,279.76
Bills receivables	467,591,793.21	1,137,537,531.35
Accounts receivables	1,994,861,024.54	2,248,341,190.25
Receivables financing		
Prepayments	214,665,035.97	126,230,480.63
Other receivables	81,768,661.27	56,912,974.18
Of which: Interest receivables		
Dividends receivables	32,732,117.21	
Inventories	1,778,322,090.88	1,561,207,468.12
Contract assets		
Held-for-sale assets		
Non-current assets due within one year	373,782,998.46	270,562,589.36
Other current assets	251,173,619.40	67,169,409.39
Total current assets	12,479,794,398.92	16,118,011,547.10
Non-current assets:		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments	1,280,523,708.13	1,078,968,804.45
Other equity instrument investments	2,184,862,262.57	522,975,348.60
Other non-current financial assets		
Investment properties	8,454,308.13	9,084,970.71
Fixed assets	4,087,634,441.39	4,054,345,129.01
Construction in progress	331,961,012.86	234,180,002.38
Productive biological assets		
Oil and gas assets		
Right-of-use assets	184,351,520.80	33,090,291.50
Intangible assets	451,267,844.25	468,847,878.26
Development expenditure	423,300,262.03	364,875,894.36
Goodwill	1,094,527,799.82	124,911,302.94
Long-term deferred expenses	152,385,769.40	159,862,729.57
Deferred income tax assets	447,094,712.81	427,716,034.59
Other non-current assets	120,032,615.97	388,601,515.01
Total non-current assets	10,766,396,258.16	7,867,459,901.38
Total assets	23,246,190,657.08	23,985,471,448.48

Item	Amount at the end of the Period	Amount at the beginning of the year
Current liabilities:		
Short-term loans	3,158,960,134.02	2,120,000,000.00
Financial liabilities held for trading	10,434.04	418,783.64
Bills payables	818,684,988.13	785,490,545.87
Accounts payables	502,959,309.30	532,802,335.77
Receipts in advance		
Contract liabilities	60,491,839.96	104,381,754.34
Employee benefits payables	251,713,933.16	366,922,904.59
Tax and surcharge payables	176,085,145.51	199,427,216.06
Other payables	3,415,216,083.17	2,930,288,767.84
Of which: Interest payables		
Dividends payables	652,730,647.22	9,017,248.88
Held-for-sale liabilities		
Non-current liabilities due within one year	16,658,183.63	173,221,455.56
Other current liabilities	3,870,761.81	6,799,037.11
Total current liabilities	8,404,650,812.73	7,219,752,800.78
Non-current liabilities:		
Long-term loans	185,800,000.00	749,356,599.04
Bonds payables		
Leasing liabilities	22,996,270.41	17,323,404.86
Long-term payables		
Long-term employee benefits payables	3,605,209.72	
Provisions		
Deferred gains	244,706,575.39	242,158,993.30
Deferred income tax liabilities	243,093,080.73	209,779,488.54
Other non-current liabilities	1,891,099.09	
Total non-current liabilities	702,092,235.34	1,218,618,485.74
Total liabilities	9,106,743,048.07	8,438,371,286.52
Share capital	887,907,171.00	887,907,171.00
Other equity instruments		
Of which: Preferred shares		
Perpetual bonds		
Capital reserve	454,796,243.71	271,389,337.35
Less: Treasury shares		
Other comprehensive income	-174,469,652.13	-9,142,282.85
Special reserve		
Surplus reserve		
Undistributed profits	11,850,929,110.57	12,738,196,339.64
Total equity attributable to shareholders of the parent company	13,019,162,873.15	13,888,350,565.14
Minority interests	1,120,284,735.86	1,658,749,596.82
Total shareholders' (or owners') equity	14,139,447,609.01	15,547,100,161.96
Total liabilities and shareholders' (or owners') equity	23,246,190,657.08	23,985,471,448.48

Legal Representative:
Liu Daping

Person-in-charge of Accounting Work:
Wang Sheng

Head of Accounting Department:
Wang Sheng

Consolidated Income Statement from the Beginning of the Year to the End of the Reporting Period

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount for the Period	Amount for the Previous Period
I. Operating income	7,319,308,094.92	9,115,914,290.40
Less: Operating costs	2,909,950,647.78	3,064,284,474.55
Tax and surcharge	91,428,419.26	113,801,771.98
Selling expenses	1,689,331,343.85	2,603,992,435.13
Administrative expenses	432,682,307.64	449,643,456.11
R&D expenses	563,990,473.77	683,264,467.54
Finance expenses	-42,824,764.05	-189,000,313.28
Of which: Interest expenses	31,119,434.66	43,698,120.84
Interest income	125,879,577.05	242,202,781.32
Add: Other income	59,485,891.31	95,669,068.02
Investment income (“-” represents losses)	154,542,499.17	48,706,390.01
Of which: Income from investment in associates and joint ventures	60,647,261.33	45,883,152.74
Derecognition of income from financial assets at amortized cost (“-” represents losses)		
Gains from hedging net exposure (“-” represents losses)		
Gains from changes in fair value (“-” represents losses)	-17,041,013.16	2,447,091.77
Credit impairment loss (“-” represents losses)	-1,199,492.43	-7,890,079.59
Asset impairment loss (“-” represents losses)	-27,510,909.07	-17,617,025.91
Gains from disposal of assets (“-” represents losses)	-404,273.13	-315,529.31
II. Operating profit (“-” represents losses)	1,842,622,369.36	2,510,927,913.36
Add: Non-operating income	6,935,059.49	2,774,839.97
Less: Non-operating expenditure	16,610,136.50	17,157,716.63
III. Total profit (“-” represents total losses)	1,832,947,292.35	2,496,545,036.70
Less: Income tax expenses	280,710,013.96	366,290,379.07
IV. Net profit (“-” represents net losses)	1,552,237,278.39	2,130,254,657.63
(I) Classified by continuing operations:		
Of which: Net profit from continuing operations (“-” represents net losses)	1,552,237,278.39	2,130,254,657.63
Net profit from discontinued operations (“-” represents net losses)		
(II) Classified by attribution to ownership:		
Of which: Net profit attributable to shareholders of the parent company (“-” represents net losses)	1,288,105,339.88	1,754,100,316.30
Profit and loss attributable to minority interests (“-” represents net losses)	264,131,938.51	376,154,341.33

Item	Amount for the Period	Amount for the Previous Period
V. Other comprehensive net income after taxation	-173,565,995.22	-59,022,809.11
Other comprehensive net income after taxation attributable to shareholders of the parent company	-165,327,369.28	-60,177,610.18
(I) Other comprehensive income not to be reclassified into profit or loss	-77,427,902.20	-2,817,351.10
1. Changes in remeasurement of defined benefit plans		
2. Other comprehensive income not to be reclassified into profit or loss under the equity method		
3. Changes in fair value of other equity instrument investments	-77,427,902.20	-2,817,351.10
4. Changes in fair value of enterprise's own credit risk		
5. Others		
(II) Other comprehensive income to be reclassified into profit or loss	-87,899,467.08	-57,360,259.08
1. Other comprehensive income to be reclassified into profit or loss under the equity method	-99,012.73	4,899.65
2. Changes in fair value of other debt investments		
3. Financial assets reclassified into other comprehensive income		
4. Credit impairment provision for other debt investments		
5. Reserve for cash flow hedging (effective portion of profit or loss from cash flow hedging)		
6. Translation differences of financial statements denominated in foreign currency	-87,800,454.35	-57,365,158.73
7. Others		
Other comprehensive net income after taxation attributable to minority interests	-8,238,625.94	1,154,801.07
VI. Total comprehensive income	1,378,671,283.17	2,071,231,848.52
Total comprehensive income attributable to shareholders of the parent company	1,122,777,970.60	1,693,922,706.12
Total comprehensive income attributable to minority interests	255,893,312.57	377,309,142.40
VII. Earnings per share		
(I) Basic earnings per share	1.45	1.96
(II) Diluted earnings per share	1.45	1.96

Legal Representative:
Liu Daping

Person-in-charge of Accounting Work:
Wang Sheng

Head of Accounting Department:
Wang Sheng

Consolidated Cash Flow Statement from the Beginning of the Year to the End of the Reporting Period

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount for the Period	Amount for the Previous Period
I. Cash flow from operating activities:		
Cash received from sales of goods and services rendered	8,769,570,553.38	9,744,458,934.54
Refund of taxes and levies	83,611,664.69	67,343,277.76
Cash received relating to other operating activities	231,162,084.83	343,644,802.31
Subtotal of cash inflow from operating activities	9,084,344,302.90	10,155,447,014.61
Cash paid for purchase of goods and services received	2,279,804,776.60	2,340,361,803.79
Cash paid to and on behalf of employees	1,409,853,284.39	1,352,705,534.48
Payments for various taxes and levies	824,856,282.51	1,067,714,253.16
Cash paid relating to other operating activities	2,077,902,280.58	2,869,244,170.34
Subtotal of cash outflow from operating activities	6,592,416,624.08	7,630,025,761.77
Net cash flow from operating activities	2,491,927,678.82	2,525,421,252.84
II. Cash flow from investing activities:		
Cash received from disposal of investments	4,280,504,941.46	4,905,983,830.21
Cash received on investment income	62,821,002.41	27,860,344.04
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	837,715.00	1,281,158.00
Net cash received from disposal of subsidiaries and other operating units		
Cash received relating to other investing activities	1,855,603,200.00	125,249.03
Subtotal of cash inflow from investing activities	6,199,766,858.87	4,935,250,581.28
Cash payments for acquisition of fixed assets, intangible assets and other long-term assets	332,819,071.16	495,411,345.73
Cash payments for investments	4,840,551,864.97	6,061,646,109.43
Net cash paid for acquisition of subsidiaries and other operating units	1,557,160,427.97	
Cash paid relating to other investing activities	128,479,829.14	4,517,355.29
Subtotal of cash outflow from investing activities	6,859,011,193.24	6,561,574,810.45
Net cash flow from investing activities	-659,244,334.37	-1,626,324,229.17

Item	Amount for the Period	Amount for the Previous Period
III. Cash flow from financing activities:		
Cash received from investments	39,500,000.00	28,799,064.00
Of which: Cash received by subsidiaries from investments of minority interests	39,500,000.00	28,799,064.00
Cash received from borrowings	3,918,403,854.41	2,870,140,000.00
Cash received relating to other financing activities	8,020,104.14	
Subtotal of cash inflow from financing activities	3,965,923,958.55	2,898,939,064.00
Cash paid on repayment of debts	3,648,759,885.14	2,935,993,209.00
Cash paid for distribution of dividends, profits or interest	2,295,331,018.50	1,126,904,288.33
Of which: Dividends and profits paid to minority interests by subsidiaries	729,643,268.12	105,966,560.00
Cash paid relating to other financing activities	23,748,829.48	586,793,757.30
Subtotal of cash outflow from financing activities	5,967,839,733.12	4,649,691,254.63
Net cash flow from financing activities	-2,001,915,774.57	-1,750,752,190.63
IV. Effect of changes in foreign exchange rates on cash and cash equivalents	-121,231,387.38	-56,627,486.05
V. Net increase in cash and cash equivalents	-290,463,817.50	-908,282,653.01
Add: Balance of cash and cash equivalents at the beginning of the Period	7,440,362,084.37	10,817,816,661.30
VI. Balance of cash and cash equivalents at the end of the Period	7,149,898,266.87	9,909,534,008.29

Legal Representative:
Liu Daping

Person-in-charge of Accounting Work:
Wang Sheng

Head of Accounting Department:
Wang Sheng

(II) Adjustments to the Financial Statements as at the Beginning of the Year Due to the Application of New Accounting Standards for the First Time Since 2026

☐ Applicable ☒ Not Applicable

(III) Audit Report

Whether the third quarterly report has been audited

☐ Yes ☒ No

The third quarterly report of the Company has not been audited.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
23 October 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (Chairman and President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

* For identification purpose only